Tyra Biosciences, Inc. (TYRA): Price and Financial Metrics


Tyra Biosciences, Inc. (TYRA): $6.78

-0.17 (-2.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TYRA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TYRA Stock Price Chart Interactive Chart >

Price chart for TYRA

TYRA Price/Volume Stats

Current price $6.78 52-week high $20.51
Prev. close $6.95 52-week low $4.93
Day low $6.55 Volume 21,700
Day high $7.00 Avg. volume 74,053
50-day MA $7.07 Dividend yield N/A
200-day MA $8.63 Market Cap 286.10M

Tyra Biosciences, Inc. (TYRA) Company Bio


Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.


TYRA Latest News Stream


Event/Time News Detail
Loading, please wait...

TYRA Latest Social Stream


Loading social stream, please wait...

View Full TYRA Social Stream

Latest TYRA News From Around the Web

Below are the latest news stories about TYRA BIOSCIENCES INC that investors may wish to consider to help them evaluate TYRA as an investment opportunity.

Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300

Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced the initiation of its SURF301 Phase 1/2 clinical study, with first patient dosed with TYRA-300. TYRA-300, the Company's lead product candidate stemming from its SNÅP platform, is an oral, FGFR3-selective inhibitor for the treatment of metastatic urothelial carcinoma of the bladder and urinary

Yahoo | November 29, 2022

How Much Upside is Left in Tyra Biosciences, Inc. (TYRA)? Wall Street Analysts Think 184%

The mean of analysts' price targets for Tyra Biosciences, Inc. (TYRA) points to an 184.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 24, 2022

Results from Tyra Biosciences Inc. (TYRA) show risk

As of Tuesday, Tyra Biosciences Inc.’s (NASDAQ:TYRA) stock closed at $6.78, down from $6.95 the previous day. While Tyra Biosciences Inc. has underperformed by -2.45%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TYRA fell by -70.37%, with highs and lows ranging from $27.17 to $4.93, […]

US Post News | November 23, 2022

Tyra Biosciences to Present at Upcoming Investor Conferences

Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences in November:

Yahoo | November 10, 2022

Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 179%: Read This Before Placing a Bet

The consensus price target hints at a 178.5% upside potential for Tyra Biosciences, Inc. (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | November 8, 2022

Read More 'TYRA' Stories Here

TYRA Price Returns

1-mo 4.31%
3-mo N/A
6-mo -6.22%
1-year -61.76%
3-year N/A
5-year N/A
YTD -51.81%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.593 seconds.